Novartis AG (0QLR.IL)
IOB - IOB Delayed price. Currency in CHF
Add to watchlist
At close: 06:09PM GMT
| Previous close | 84.06 |
| Open | 84.15 |
| Bid | 82.12 x N/A |
| Ask | 86.33 x N/A |
| Day's range | 83.65 - 84.74 |
| 52-week range | 73.79 - 94.77 |
| Volume | |
| Avg. volume | 967,778 |
| Market cap | 193.116B |
| Beta (5Y monthly) | 0.49 |
| PE ratio (TTM) | 26.24 |
| EPS (TTM) | 3.21 |
| Earnings date | N/A |
| Forward dividend & yield | 3.20 (3.78%) |
| Ex-dividend date | 09 Mar 2023 |
| 1y target est | N/A |
Globe NewswireLatest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival (OS)1,2 iDFS benefit remains consistent across key patient subgroups; among patients with stage II and stage III tumors, Kisqali lowered risk by 30% and 24.5%, respectively1,2 Latest analysis continues to show a well-tolerated safety profile in line with pre
ZacksPharma Stock Roundup: ABBV to Buy CERE, JNJ's 2024 View, LLY & NVS Get FDA Nod
AbbVie (ABBV) offers to acquire Cerevel Therapeutics for $8.7 billion. J&J (JNJ) announces sales and earnings growth expectations for 2024.
ZacksNovartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug
Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.
© 2023 Yahoo. All rights reserved.